Semaglutide (Ozempic®) for the treatment of adults with insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exercise
The National Health Care Institute carried out a marginal assessment of whether semaglutide (Ozempic®) is interchangeable with a drug currently included in the Medicine Reimbursement System (GVS).
Registration
Semaglutide belongs to the pharmacotherapeutic group of GLP-1 (glucagon-like peptide 1) receptor agonists. It is available as 1.34 mg/ml semaglutide for injection in a pre-filled pen with 1.5 ml solution.
It is registered for the treatment of adults with insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exercise as monotherapy when metformin is considered inappropriate due to intolerance or contraindications, or in addition to other medicinal products for the treatment of diabetes mellitus type 2.
Advice
Based on the current criteria, semaglutide (Ozempic®) is interchangeable with the other GLP-1 receptor agonists that are jointly included in cluster 0A10BXAP V of the GVS, namely exenatide, liraglutide, lixisenatide and dulaglutide.
Based on our marginal assessment, the National Health Care Institute advised the Minister to include semaglutide (Ozempic®) on list 1A, in cluster 0A10BXAP V, with a standard dose of 0.07 mg a day.
In addition we advised the Minister that the same reimbursement conditions should apply to the inclusion of semaglutide as to the other GLP-1 receptor agonists in cluster 0A10BXAP V.
This report is a summary of recommendations by the National Health Care Institute. The original text of this excerpt is in Dutch.